within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EX10_Midostaurin;

model Midostaurin
  extends Pharmacolibrary.Drugs.ATC.L.L01EX10;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L01EX10</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Midostaurin is a multi-targeted kinase inhibitor used primarily for the treatment of acute myeloid leukemia (AML) with FLT3 mutations and advanced systemic mastocytosis. It is an orally administered drug approved in several regions including the United States and Europe for these indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adult patients with cancer, following multiple oral doses of midostaurin 50 mg twice daily.</p><h4>References</h4><ol><li><p>Wang, Y, et al., &amp; Schran, H (2008). Dose- and time-dependent pharmacokinetics of midostaurin in patients with diabetes mellitus. <i>Journal of clinical pharmacology</i> 48(6) 763–775. DOI:<a href=&quot;https://doi.org/10.1177/0091270008318006&quot;>10.1177/0091270008318006</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18508951/&quot;>https://pubmed.ncbi.nlm.nih.gov/18508951</a></p></li><li><p>Sechaud, R, et al., &amp; Menssen, HD (2024). Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participants. <i>Cancer chemotherapy and pharmacology</i> 93(5) 439–453. DOI:<a href=&quot;https://doi.org/10.1007/s00280-023-04635-3&quot;>10.1007/s00280-023-04635-3</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38270613/&quot;>https://pubmed.ncbi.nlm.nih.gov/38270613</a></p></li><li><p>Gu, H, et al., &amp; Einolf, HJ (2025). Physiologically based pharmacokinetic modeling of midostaurin and metabolites at steady-state to bridge drug interaction scenarios in lieu of clinical trials. <i>Drug metabolism and disposition: the biological fate of chemicals</i> 53(3) 100036–None. DOI:<a href=&quot;https://doi.org/10.1016/j.dmd.2025.100036&quot;>10.1016/j.dmd.2025.100036</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39985984/&quot;>https://pubmed.ncbi.nlm.nih.gov/39985984</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Midostaurin;
